Literature DB >> 28887614

The pro-fibrotic connective tissue growth factor (CTGF/CCN2) correlates with the number of necrotic-regenerative foci in dystrophic muscle.

María Gabriela Morales1, María José Acuña1, Daniel Cabrera1,2, Roel Goldschmeding3, Enrique Brandan4.   

Abstract

Connective tissue growth factor (CTGF/CCN2) has strong inflammatory and profibrotic activities. Its expression is enhanced in skeletal muscular dystrophies such as Duchenne muscular dystrophy (DMD), a myopathy characterized by exacerbated inflammation and fibrosis. In dystrophic tissue, necrotic-regenerative foci, myofibroblasts, newly-regenerated muscle fibers and necrosis all occur simultaneously. To determine if CCN2 is involved in the appearance of the foci, we studied their presence and characteristics in mdx mice (DMD mouse model) compared to mdx mice hemizygous for CCN2 (mdx-Ccn2+/-). We used laser capture microdissection followed by gene expression and immunofluorescence analyses to investigate fibrotic, inflammation and regeneration markers in damaged and non-damaged areas in mdx and mdx-Ccn2+/- skeletal muscle. Mdx mice foci express elevated mRNAs levels of transforming growth factor type beta, collagen, fibronectin, the myofribroblast marker α-SMA, and the myogenic transcription factor myogenin. Mdx foci also show elevated levels of MCP-1 and CD-68 positive cells, indicating that CCN2 could be inducing an inflammatory response. We found a significant reduction in the number of foci in mdx-Ccn2+/- mice muscle. Fibrotic and inflammatory markers were also decreased in these foci. We did not observe any difference in Pax7 mRNA levels, a marker for satellite cells, in mdx mice compared to mdx-Ccn2+/- mice. Thus, CCN2 appears to be involved in the fibrotic response as well as in the inflammatory response in the dystrophic skeletal muscle.

Entities:  

Keywords:  CTGF/CCN2; Fibrosis; Inflammation; Muscular dystrophy; Necrotic-regenerative focus

Year:  2017        PMID: 28887614      PMCID: PMC5842176          DOI: 10.1007/s12079-017-0409-3

Source DB:  PubMed          Journal:  J Cell Commun Signal        ISSN: 1873-9601            Impact factor:   5.782


  44 in total

1.  [Muscle regeneration: the effect of the basal lamina, size of the lesion and inflammatory response in C57BL10/ScSn mice].

Authors:  A Fargas; J Roma; M Roig
Journal:  Rev Neurol       Date:  2002 Feb 16-28       Impact factor: 0.870

2.  Motor nerve regulates muscle extracellular matrix proteoglycan expression.

Authors:  R Fadic; E Brandan; N C Inestrosa
Journal:  J Neurosci       Date:  1990-11       Impact factor: 6.167

3.  Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy.

Authors:  Maria Gabriela Morales; Jaime Gutierrez; Claudio Cabello-Verrugio; Daniel Cabrera; Kenneth E Lipson; Roel Goldschmeding; Enrique Brandan
Journal:  Hum Mol Genet       Date:  2013-07-30       Impact factor: 6.150

4.  CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC.

Authors:  Youjun Chen; Ingrid E Blom; Susan Sa; Roel Goldschmeding; David J Abraham; Andrew Leask
Journal:  Kidney Int       Date:  2002-10       Impact factor: 10.612

5.  Connective tissue growth factor is overexpressed in muscles of human muscular dystrophy.

Authors:  Guilian Sun; Kazuhiro Haginoya; Yanling Wu; Yoko Chiba; Tohru Nakanishi; Akira Onuma; Yuko Sato; Masaharu Takigawa; Kazuie Iinuma; Shigeru Tsuchiya
Journal:  J Neurol Sci       Date:  2007-11-09       Impact factor: 3.181

Review 6.  TGF-beta and fibrosis in different organs - molecular pathway imprints.

Authors:  Dirk Pohlers; Julia Brenmoehl; Ivonne Löffler; Cornelia K Müller; Carola Leipner; Stefan Schultze-Mosgau; Andreas Stallmach; Raimund W Kinne; Gunter Wolf
Journal:  Biochim Biophys Acta       Date:  2009-06-17

7.  [Muscle regeneration following glycerol injection mimic that of mdx-mice degenerative-regenerative groups].

Authors:  M Roig-Quilis; J Roma; M Marotta; Y Sarria; A Fargas
Journal:  Rev Neurol       Date:  2004 Jun 16-30       Impact factor: 0.870

8.  Longitudinal pathologic study of the gastrocnemius muscle group in mdx mice.

Authors:  Manuel Roig; Josep Roma; Arnau Fargas; Francina Munell
Journal:  Acta Neuropathol       Date:  2003-10-07       Impact factor: 17.088

9.  Angiotensin II receptor type 1 blockade decreases CTGF/CCN2-mediated damage and fibrosis in normal and dystrophic skeletal muscles.

Authors:  Claudio Cabello-Verrugio; María Gabriela Morales; Daniel Cabrera; Carlos P Vio; Enrique Brandan
Journal:  J Cell Mol Med       Date:  2012-04       Impact factor: 5.310

10.  Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease?

Authors:  Andrew Leask; Sunil K Parapuram; Xu Shi-Wen; D J Abraham
Journal:  J Cell Commun Signal       Date:  2009-01-21       Impact factor: 5.782

View more
  18 in total

1.  Blockade of Bradykinin receptors worsens the dystrophic phenotype of mdx mice: differential effects for B1 and B2 receptors.

Authors:  María José Acuña; Daniela Salas; Adriana Córdova-Casanova; Meilyn Cruz-Soca; Carlos Céspedes; Carlos P Vio; Enrique Brandan
Journal:  J Cell Commun Signal       Date:  2017-12-17       Impact factor: 5.782

Review 2.  Multifunctional regulatory protein connective tissue growth factor (CTGF): A potential therapeutic target for diverse diseases.

Authors:  Minyang Fu; Dandan Peng; Tianxia Lan; Yuquan Wei; Xiawei Wei
Journal:  Acta Pharm Sin B       Date:  2022-01-19       Impact factor: 14.903

3.  Adaptations in Hippo-Yap signaling and myofibroblast fate underlie scar-free ear appendage wound healing in spiny mice.

Authors:  Chris M Brewer; Branden R Nelson; Paul Wakenight; Sarah J Collins; Daryl M Okamura; Xiu Rong Dong; William M Mahoney; Aaron McKenna; Jay Shendure; Andrew Timms; Kathleen J Millen; Mark W Majesky
Journal:  Dev Cell       Date:  2021-10-04       Impact factor: 13.417

Review 4.  CTGF/CCN2 from Skeletal Muscle to Nervous System: Impact on Neurodegenerative Diseases.

Authors:  David Gonzalez; Enrique Brandan
Journal:  Mol Neurobiol       Date:  2019-01-28       Impact factor: 5.590

5.  CCN2 participates in overload-induced skeletal muscle hypertrophy.

Authors:  Jennifer M Petrosino; Jacob Z Longenecker; Colin D Angell; Scott A Hinger; Colton R Martens; Federica Accornero
Journal:  Matrix Biol       Date:  2022-01-16       Impact factor: 11.583

Review 6.  Histopathology of Duchenne muscular dystrophy in correlation with changes in proteomic biomarkers.

Authors:  Margit Zweyer; Hemmen Sabir; Paul Dowling; Stephen Gargan; Sandra Murphy; Dieter Swandulla; Kay Ohlendieck
Journal:  Histol Histopathol       Date:  2021-12-07       Impact factor: 2.303

7.  Increased Fibrogenic Gene Expression in Multifidus Muscles of Patients With Chronic Versus Acute Lumbar Spine Pathology.

Authors:  Bahar Shahidi; Kathleen M Fisch; Michael C Gibbons; Samuel R Ward
Journal:  Spine (Phila Pa 1976)       Date:  2020-02-15       Impact factor: 3.241

8.  Genetic manipulation of CCN2/CTGF unveils cell-specific ECM-remodeling effects in injured skeletal muscle.

Authors:  Jennifer M Petrosino; Andrew Leask; Federica Accornero
Journal:  FASEB J       Date:  2018-09-14       Impact factor: 5.834

9.  Genetic reduction of the extracellular matrix protein versican attenuates inflammatory cell infiltration and improves contractile function in dystrophic mdx diaphragm muscles.

Authors:  Natasha L McRae; Alex B Addinsall; Kirsten F Howlett; Bryony McNeill; Daniel R McCulloch; Nicole Stupka
Journal:  Sci Rep       Date:  2020-07-06       Impact factor: 4.379

10.  Platelet Derived Growth Factor-AA Correlates With Muscle Function Tests and Quantitative Muscle Magnetic Resonance in Dystrophinopathies.

Authors:  Alicia Alonso-Jiménez; Esther Fernández-Simón; Daniel Natera-de Benito; Carlos Ortez; Carme García; Elena Montiel; Izaskun Belmonte; Irene Pedrosa; Sonia Segovia; Patricia Piñol-Jurado; Ana Carrasco-Rozas; Xavier Suárez-Calvet; Cecilia Jimenez-Mallebrera; Andrés Nascimento; Jaume Llauger; Claudia Nuñez-Peralta; Paula Montesinos; Jorge Alonso-Pérez; Eduard Gallardo; Isabel Illa; Jordi Díaz-Manera
Journal:  Front Neurol       Date:  2021-06-11       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.